Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications

Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP

(2012) Hiroyuki Kusuhara et al.   BRITISH JOURNAL OF PHARMACOLOGY

Progesterone receptor downregulates breast cancer resistance protein expression via binding to the progesterone response element in breast cancer

(2012) Xiaojuan Wu et al.   CANCER SCIENCE

Pharmacogenetic Determinants of Statin-Induced Reductions in C-Reactive Protein

(2012) Audrey Y. Chu et al.   Circulation-Cardiovascular Genetics

Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction

(2012) Daniel I. Chasman et al.   Circulation-Cardiovascular Genetics

Efflux transporters in the blood–brain interfaces –in vitroandin vivomethods and correlations

(2012) Péter Krajcsi et al.   Expert Opinion on Drug Metabolism & Toxicology

ABCG2 null alleles define the Jr(a−) blood group phenotype

(2012) Teresa Zelinski et al.   NATURE GENETICS

Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior

(2012) Carole Saison et al.   NATURE GENETICS

Bioavailability of the Glucuronide and Sulfate Conjugates of Genistein and Daidzein in Breast Cancer Resistance Protein 1 Knockout Mice

(2011) A. I. Alvarez et al.   DRUG METABOLISM AND DISPOSITION

Impact of Abcc2 [Multidrug Resistance-Associated Protein (Mrp) 2], Abcc3 (Mrp3), and Abcg2 (Breast Cancer Resistance Protein) on the Oral Pharmacokinetics of Methotrexate and Its Main Metabolite 7-Hydroxymethotrexate

(2011) M. L. H. Vlaming et al.   DRUG METABOLISM AND DISPOSITION

Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics

(2011) B. Poller et al.   DRUG METABOLISM AND DISPOSITION

Population Differences in Major Functional Polymorphisms of Pharmacokinetics/pharmacodynamics-related Genes in Eastern Asians and Europeans: Implications in the Clinical Trials for Novel Drug Development

(2011) Kouichi Kurose et al.   Drug Metabolism and Pharmacokinetics

Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration

(2011) Seng Chuan Tang et al.   INTERNATIONAL JOURNAL OF CANCER

Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors

(2011) Yasuo Uchida et al.   JOURNAL OF NEUROCHEMISTRY

Quantitative Evaluation of the Impact of Active Efflux by P-Glycoprotein and Breast Cancer Resistance Protein at the Blood-Brain Barrier on the Predictability of the Unbound Concentrations of Drugs in the Brain Using Cerebrospinal Fluid Concentration as a Surrogate

(2011) H. Kodaira et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Double-Transduced MDCKII Cells To Study Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Interplay in Drug Transport across the Blood−Brain Barrier

(2011) Birk Poller et al.   MOLECULAR PHARMACEUTICS

ABCG2/BCRP Dysfunction as a Major Cause of Gout

(2011) Hirotaka Matsuo et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug–Drug Interactions

(2011) Maria Karlgren et al.   PHARMACEUTICAL RESEARCH

Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction

(2010) Kristian M. Bailey et al.   Circulation-Cardiovascular Genetics

Drug Transporters and Imatinib Treatment: Implications for Clinical Practice

(2010) K. Eechoute et al.   CLINICAL CANCER RESEARCH

ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin

(2010) B Tomlinson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Attenuation of Intestinal Absorption by Major Efflux Transporters: Quantitative Tools and Strategies Using a Caco-2 Model

(2010) X. Lin et al.   DRUG METABOLISM AND DISPOSITION

Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level

(2010) Kyoung-Ah Kim et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins

(2010) Miao Hu et al.   Expert Opinion on Drug Metabolism & Toxicology

Drug transport by breast cancer resistance protein

(2010) Maren Poguntke et al.   Expert Opinion on Drug Metabolism & Toxicology

ABCB1 and ABCG2 expression in the placenta and fetus: an interspecies comparison

(2010) Päivi Myllynen et al.   Expert Opinion on Drug Metabolism & Toxicology

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP

(2010) Nienke A. de Vries et al.   INVESTIGATIONAL NEW DRUGS

Involvement of Breast Cancer Resistance Protein (BCRP1/ABCG2) in the Bioavailability and Tissue Distribution oftrans-Resveratrol in Knockout Mice

(2010) Irene Alfaras et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone

(2010) H. Kodaira et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain

(2010) S. Agarwal et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation

(2010) J. S. Lagas et al.   MOLECULAR CANCER THERAPEUTICS

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1

(2010) P. Annaert et al.   XENOBIOTICA

Functionally Overlapping Roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the Elimination of Methotrexate and Its Main Toxic Metabolite 7-Hydroxymethotrexate In vivo

(2009) M. L.H. Vlaming et al.   CLINICAL CANCER RESEARCH

Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment

(2009) J. S. Lagas et al.   CLINICAL CANCER RESEARCH

Transporter Pharmacogenetics and Statin Toxicity

(2009) M Niemi   CLINICAL PHARMACOLOGY & THERAPEUTICS

ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin

(2009) J E Keskitalo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice

(2009) L. Zhou et al.   DRUG METABOLISM AND DISPOSITION

Complex Pharmacokinetic Behavior of Ezetimibe Depends on Abcc2, Abcc3, and Abcg2

(2009) D. R. de Waart et al.   DRUG METABOLISM AND DISPOSITION

Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs

(2009) Ichiro Ieiri et al.   Expert Opinion on Drug Metabolism & Toxicology

ABCG2: the key to chemoresistance in cancer stem cells?

(2009) Yi An et al.   Expert Opinion on Drug Metabolism & Toxicology

Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity

(2009) Nielka P. van Erp et al.   JOURNAL OF CLINICAL ONCOLOGY

Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression

(2009) Pei-Chieng Cha et al.   JOURNAL OF HUMAN GENETICS

Oral Sulfasalazine as a Clinical BCRP Probe Substrate: Pharmacokinetic Effects of Genetic Variation (C421A) and Pantoprazole Coadministration

(2009) Kimberly K. Adkison et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib

(2009) Y. Chen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

ABC Transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) Expression in the Developing Human CNS

(2009) M. Daood et al.   NEUROPEDIATRICS

Different effects of theABCG2c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin

(2009) Jenni E Keskitalo et al.   PHARMACOGENOMICS

Common Polymorphisms Influencing Serum Uric Acid Levels Contribute to Susceptibility to Gout, but Not to Coronary Artery Disease

(2009) Klaus Stark et al.   PLoS One

Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout

(2009) O. M. Woodward et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Meta-Analysis of 28,141 Individuals Identifies Common Variants within Five New Loci That Influence Uric Acid Concentrations

(2009) Melanie Kolz et al.   PLoS Genetics

QSAR analysis and molecular modeling of ABCG2-specific inhibitors

(2008) E. Nicolle et al.   ADVANCED DRUG DELIVERY REVIEWS

Physiological and pharmacological roles of ABCG2 (BCRP): Recent findings in Abcg2 knockout mice

(2008) Maria L.H. Vlaming et al.   ADVANCED DRUG DELIVERY REVIEWS

Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2

(2008) Hiroshi Nakagawa et al.   BIOCHEMICAL JOURNAL

TheABCG2C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects

(2008) Kimberly K. Adkison et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients

(2008) Suman Lal et al.   CANCER SCIENCE

The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies

(2008) SU Yasuda et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans

(2008) Y Yamasaki et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N- -6-[5-( methyl)-2-furyl]-4-quinazolinamine; GW572016)

(2008) J. W. Polli et al.   DRUG METABOLISM AND DISPOSITION

Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) on Pharmacokinetics and Central Nervous System Penetration of Abacavir and Zidovudine in the Mouse

(2008) N. Giri et al.   DRUG METABOLISM AND DISPOSITION

Transport of Diclofenac by Breast Cancer Resistance Protein (ABCG2) and Stimulation of Multidrug Resistance Protein 2 (ABCC2)-Mediated Drug Transport by Diclofenac and Benzbromarone

(2008) J. S. Lagas et al.   DRUG METABOLISM AND DISPOSITION

Pharmacogenomics of MRP Transporters (ABCC1-5) and BCRP (ABCG2)

(2008) Ulrike Gradhand et al.   DRUG METABOLISM REVIEWS

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

(2008) Roos L. Oostendorp et al.   INVESTIGATIONAL NEW DRUGS

Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers

(2008) Jennifer J Kiser et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity

(2008) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Brain penetration of ivermectin and selamectin inmdr1a,bP-glycoprotein- andbcrp- deficient knockout mice

(2008) J. GEYER et al.   JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice

(2008) S. Marchetti et al.   MOLECULAR CANCER THERAPEUTICS

Quantitative Atlas of Membrane Transporter Proteins: Development and Application of a Highly Sensitive Simultaneous LC/MS/MS Method Combined with Novel In-silico Peptide Selection Criteria

(2008) Junichi Kamiie et al.   PHARMACEUTICAL RESEARCH

Major SNP (Q141K) Variant of Human ABC Transporter ABCG2 Undergoes Lysosomal and Proteasomal Degradations

(2008) Tomoka Furukawa et al.   PHARMACEUTICAL RESEARCH

Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe

(2008) Bradley L. Urquhart et al.   Pharmacogenetics and Genomics

Pharmacogenomic importance of ABCG2

(2008) George Cusatis et al.   PHARMACOGENOMICS

The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane

(2007) M. Huls et al.   KIDNEY INTERNATIONAL